Can a vaccine stop cancer? The HPV story, study by study
Last reviewed November 15, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Human papillomavirus (HPV) is a very common virus spread by sexual contact. Most infections clear on their own, but some high-risk types can cause cancer of the cervix and other areas years later.
Below we follow the research from the 1983 discovery to vaccine trials and real-world results in millions of people.
Related pages: HPV infection · Cervical precancer or cancer · Genital warts
The bottom line
- HPV causes almost all cervical cancer.
- The vaccine prevents infection and precancer, and in large countrywide studies it greatly lowers cervical cancer.
- It works best when given before any exposure to HPV, around age 12 to 13.
- Exactly how long protection lasts. So far it has held steady for more than 10 years.
- Whether one dose prevents cancer as well as two. Trials show one dose prevents infection just as well, but cancer data will take longer.
- Screening is still needed, because the vaccine doesn't cover every cancer-causing type and doesn't treat existing infection.
The studies, in order
- 1. Finding the virus (Harald zur Hausen and team, 1983 and 1984)
- 2. The vaccine trial (FUTURE II Study Group, 2007)
- 3. 1.7 million Swedish women (Lei and others, 2020)
- 4. Zero cases in Scotland (Palmer and others, 2024)
- 5. One shot in Kenya (Barnabas and others (KEN SHE trial), 2022)
- 6. One dose vs two (Kreimer and others (ESCUDDO trial), 2025)
What the evidence labels mean
HPV DNA found inside cervical cancers
What they did
Going against the common view, zur Hausen guessed that a wart virus could cause cervical cancer. His team searched cancer tissue samples from Germany, Brazil, and Kenya for virus DNA.
What they found
- In 1983 they found a new type, HPV16, in more than half of German cervical cancer samples.
- In 1984 they found HPV18. Together, HPV16 and 18 are found in about 70% of cervical cancers worldwide.
- Later work found HPV in 99.7% of cervical cancers.
What it means
This pointed to a virus as the cause, which made a vaccine possible. Zur Hausen won the Nobel Prize in 2008.
What it can't tell us
- Finding virus DNA in a tumor shows a strong link but doesn't on its own prove cause. Later lab and population studies filled that in.
- Drug companies were slow to make a vaccine. The first was approved in 2006.
Read it yourself
- Durst and zur Hausen 1983, PNASJournal
- Nobel Prize 2008 press releaseNobel Prize
Next: The vaccine trial
The vaccine prevented 98% of precancers from HPV16 and 18
What they did
12,167 women aged 15 to 26 were randomly given 3 shots of the 4-type HPV vaccine (Gardasil) or a placebo and followed for about 3 years.
What they found
- In women not already infected, the vaccine prevented 98% of serious precancer caused by HPV16 or 18.
- Counting all women, including those already infected, it prevented 44% of those precancers.
- Against serious precancer from any HPV type, it prevented 17% in all women in the first few years.
What it means
The vaccine works very well before infection and does little for an infection someone already has. That's why it's given to preteens.
What it can't tell us
- It measured precancer, not cancer, because cancer takes many years to develop.
- The trial was designed and run by the vaccine maker, with outside scientists.
Read it yourself
- FUTURE II 2007, NEJM (PubMed)PubMed
- Trial recordClinicalTrials.gov
Vaccinated before 17: 88% less cervical cancer
What they did
Researchers used national health records for 1,672,983 girls and women aged 10 to 30 from 2006 to 2017. More than 500,000 had at least one dose of the vaccine. They counted actual invasive cervical cancers.
What they found
- 19 vaccinated women got cervical cancer, compared with 538 unvaccinated women.
- Girls vaccinated before age 17 had 88% less cervical cancer.
- Women vaccinated at 17 to 30 had about half the risk.
What it means
This was the first proof at the individual level, in a whole country, that the vaccine prevents actual cancer, not just precancer.
What it can't tell us
- Women were only followed to age 30, and most cervical cancers happen later.
- It wasn't randomized. Vaccinated women might differ in other ways, though the researchers adjusted for this.
Read it yourself
- Lei 2020, NEJMJournal
Next: Zero cases in Scotland
No cervical cancer in women vaccinated at 12 or 13
What they did
Researchers linked screening, vaccine, and cancer records for about 448,000 Scottish women born 1988 to 1996. Scotland used the 2-type vaccine (Cervarix) starting in 2008.
What they found
- Not one case of invasive cervical cancer was found in women vaccinated at age 12 or 13, whatever the number of doses.
- Women vaccinated later (14 to 22) with 3 doses had lower rates than unvaccinated women: 3.2 vs 8.4 per 100,000 per year.
What it means
With early vaccination and screening, cervical cancer could become rare.
What it can't tell us
- Only about 14,600 women had 1 or 2 doses, so conclusions about fewer doses are less certain.
- These women are still young. Researchers will keep following them.
Read it yourself
- Palmer 2024, JNCIJournal
- Public Health Scotland summaryGovernment
Next: One shot in Kenya
A single dose protected 97.5% against HPV16 and 18
What they did
2,275 women aged 15 to 20 in Kenya were randomly given one dose of either of two HPV vaccines, or a meningitis vaccine for comparison.
What they found
- After 18 months, one dose of either HPV vaccine was 97.5% effective against lasting HPV16 and 18 infection.
- The 9-type vaccine was 89% effective against all 7 cancer-causing types it covers.
What it means
One dose could make vaccination much cheaper and easier, especially where cervical cancer is most common. In 2022 the World Health Organization said one or two doses can be used.
What it can't tell us
- It measured infection, not cancer.
- It compared one dose to no HPV vaccine, not to two doses.
Read it yourself
- Barnabas 2022, NEJM EvidenceJournal
Next: One dose vs two
One dose works as well as two
What they did
20,330 girls aged 12 to 16 were randomly given one or two doses of either a 2-type or 9-type HPV vaccine and followed for 5 years.
What they found
- One dose was not worse than two at preventing lasting HPV16 or 18 infection.
- Protection was over 95% in all groups.
What it means
This direct comparison settles the main question behind single-dose programs. About 90 countries already use one dose.
What it can't tell us
- It measured infection, not cancer.
- In the US, 2 or 3 doses were still the standard schedule at our last check. Follow your doctor's advice.
Read it yourself
- Kreimer 2025, NEJM (PubMed)PubMed
- Trial recordClinicalTrials.gov
More plain-language reading
- National Cancer Institute: ESCUDDO trialGovernment